Programmed Cell Death 4 (PDCD4) is a critical tumor suppressor protein that plays a pivotal role in regulating apoptosis, cell proliferation, and immune responses by modulating gene translation and transcription. PDCD4 primarily exerts its function by binding to eukaryotic initiation factor 4A (eIF4A), inhibiting its helicase activity and preventing the translation of oncogenic mRNAs with complex 5' UTRs, such as cyclin D1 and c-myc[1]. Additionally, PDCD4 suppresses the transcriptional activity of AP-1 and NF-κB, further contributing to its anti-tumor effects[2]. Downregulation or loss of PDCD4 has been observed in various cancers, including hepatocellular carcinoma, lung cancer, and breast cancer, where it correlates with tumor progression, metastasis, and poor prognosis[3]. Due to its tumor-suppressive functions, PDCD4 has emerged as a potential therapeutic target.
Dovitinib RIBOTAC 是一种靶向 RNA 的 RIBOTAC 降解剂,能特异性结合并降解 pre-miR-21,具有抗肿瘤活性,可抑制乳腺癌的转移。
Dovitinib RIBOTAC TFA 是一种靶向 RNA 的 RIBOTAC 降解剂,能特异性结合并降解 pre-miR-21,可抑制乳腺癌转移并具有抗肿瘤活性。
PDCD4-IN-1(compound 20031600)是一种 Kd 值为 350 nM 的 PDCD4 抑制剂,可促进海马神经元细胞 HT-22 中 BDNF 的表达。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号